Hematology/Oncology · West Hollywood, CA
NPI
1124051560
Since 2006
Specialty
Hematology/Oncology
Code 1744R1102X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
9201 W Sunset Blvd, Suite 310
West Hollywood, CA, 90069
Phone (310) 623-1222
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.3M
160,327 services
Medicare patients, 2024
204
Average age 75
Drug cost, 2024
$10.9M
1,975 prescriptions
Company payments, 2025
$92K
From 20 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by James R Berenson was code J9041 (injection, bortezomib, 0.1 mg), 22,288 times for 36 patients. In total James R Berenson billed 160,327 services in 64 codes, and Medicare paid $1.3M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-09-11.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9041 Injection, bortezomib, 0.1 mg | Office | 22,288 | 36 | $1.43 | $32K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 21,614 | 78 | $0.09 | $1,933 |
| Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 20,912 | 17 | $0.27 | $5,733 |
| J0897 Injection, denosumab, 1 mg | Office | 5,914 | 19 | $18.76 | $111K |
| J9227 Injection, isatuximab-irfc, 10 mg | Office | 3,036 | 27 | $49.15 | $149K |
| 85025 Blood Count | Office | 2,101 | 178 | $7.57 | $16K |
| 80053 Clinical Chemistry | Office | 1,592 | 176 | $10.28 | $16K |
| 96367 Intravenous Infusion, Hydration | Office | 1,582 | 76 | $27.37 | $43K |
| 84165 Clinical Chemistry | Office | 1,316 | 171 | $10.44 | $14K |
| 99214 Office E&M - Established | Office | 1,235 | 182 | $112.69 | $139K |
| J3489 Injection, zoledronic acid, 1 mg | Office | 1,228 | 49 | $5.08 | $6,240 |
| 96413 Chemotherapy Administration | Office | 878 | 52 | $125.22 | $110K |
| J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 627 | 11 | $33.12 | $21K |
| J3490 Unclassified drugs | Office | 614 | 38 | $0.57 | $352 |
| 96409 Chemotherapy Administration | Office | 498 | 34 | $95.35 | $47K |
By year: 2022 $4.3M for 342,497 services; 2023 $4.2M for 360,626 services; 2024 $1.3M for 160,327 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 2,101 | 178 | $7.57 | $16K |
| 80053 Clinical Chemistry | 1,592 | 176 | $10.28 | $16K |
| 84165 Clinical Chemistry | 1,316 | 171 | $10.44 | $14K |
| 36415 Venipuncture Blood Collection | 447 | 120 | $8.59 | $3,841 |
| 84100 Clinical Chemistry | 282 | 46 | $4.53 | $1,278 |
| 86334 Immunoassay | 229 | 81 | $21.73 | $4,977 |
| 84550 Clinical Chemistry | 121 | 36 | $4.43 | $536 |
| 83615 Clinical Chemistry | 62 | 37 | $5.92 | $367 |
| 85007 Blood Count | 37 | 11 | $3.72 | $138 |
| 85027 Blood Count | 36 | 11 | $6.34 | $228 |
Medicare prescription drug claims, 2024
In 2024, the drug James R Berenson prescribed most often to Medicare patients was Sarclisa (Isatuximab-Irfc), with 291 prescriptions and refills. In total James R Berenson wrote 1,975 Medicare prescriptions that cost $10.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Sarclisa Isatuximab-Irfc | 291 | 291 | 25 | $2.3M |
| Acyclovir Generic | 281 | 496 | 59 | $6,908 |
| Methylprednisolone Generic | 254 | 356 | 63 | $6,710 |
| Xgeva Denosumab | 106 | 111 | 14 | $332K |
| Pomalyst Pomalidomide | 97 | 97 | 18 | $2.2M |
| Revlimid Lenalidomide | 92 | 92 | 14 | $1.6M |
| Empliciti Elotuzumab | 76 | 76 | Under 11 | $891K |
| Darzalex Faspro Daratumumab-Hyaluronidase-Fihj | 74 | 78 | 12 | $1.2M |
| Potassium Chloride Generic | 67 | 117 | 18 | $1,476 |
| Lenalidomide Generic | 65 | 65 | 11 | $883K |
| Kyprolis Carfilzomib | 53 | 53 | Under 11 | $718K |
| Dexamethasone Generic | 50 | 90 | 14 | $1,357 |
| Allopurinol Generic | 35 | 49 | Under 11 | $204 |
| Darzalex Daratumumab | 25 | 25 | Under 11 | $186K |
| Trazodone Hcl Generic | 24 | 30 | Under 11 | $51.03 |
Brand drugs: 903 claims; generic drugs: 1,072 claims; opioid claims: 36.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid James R Berenson $92K ($50K in general payments such as food, travel and fees and $42K for research) from 20 companies. The largest payer was Genzyme Corporation with $29K.
| Company | Payments | Amount |
|---|---|---|
| Genzyme Corporation SNY | 21 | $29K |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 5 | $22K |
| Karyopharm Therapeutics Inc. KPTI | 25 | $18K |
| Janssen Biotech, Inc. JNJ | 26 | $16K |
| Pfizer Inc. PFE | 10 | $2,334 |
| Aadi Bioscience, Inc. | 2 | $1,700 |
| Merck Sharp & Dohme LLC MRK | 2 | $1,250 |
| GlaxoSmithKline, LLC. GSK | 8 | $308 |
| Sanofi-Aventis U.S. LLC SNY | 2 | $167 |
| Janssen Scientific Affairs, LLC JNJ | 2 | $148 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.